News
BOSTON, August 1, 2024 — Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators for autoimmune and inflammatory diseases, today announced the appointment of William Roush, Ph.D.,as executive vice president and head of small molecule research. In this role, Dr. Roush will be responsible for overseeing the prosecution of Odyssey’s small molecule, preclinical portfolio from target selection into early development.
“As a renowned scientist, Dr. Roush developed innovative solutions to complex problems in organic and medicinal chemistry, and under his leadership, has led multiple drug discovery programs from ideation into clinical development,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics. “With the addition of Dr. Roush to our team of drug hunters, I am confident Odyssey will continue to develop the best therapeutic candidates to potentially change the standard of care for patients living with serious immune diseases.”
Dr. Roush completed his Ph.D. degree in chemistry at Harvard University under the direction of Nobel Laureate R. B. Woodward. He held academic positions at MIT, Indiana University, the University of Michigan and most recently, the Scripps Research Institute where he is Emeritus Professor of Chemistry. Dr. Roush is the author of 380 peer-reviewed publications spanning organic and medicinal chemistry. Prior to joining Odyssey, he was the executive vice president of chemistry at IFM Therapeutics and oversaw the discovery of several product candidates for cancer and inflammation that are now in clinical development.
“The need for transformative medicines to improve patient outcomes is critical,” said Dr. Roush. “By collaborating with others at Odyssey, I hope to accelerate the discovery and development of small molecule medicines to enhance the quality of life for patients.”
About Odyssey Therapeutics
Odyssey Therapeutics is a biotechnology company focused on discovering, developing and commercializing the next-generation of immunomodulators and oncology medicines. Composed of an expert team of drug hunters, scientists and industry leaders in foundational biology, chemistry and data sciences, Odyssey is transforming drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. For more information, please visit odysseytx.com and follow Odyssey Therapeutics on X (formerly Twitter) and LinkedIn.
Media Contact
Josh George
[email protected]
503-799-7520